Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
clinicaladvisor.com4d
Alyftrek Gets FDA Approval for Cystic Fibrosis
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...
pharmaphorum6d
FDA approves flurry of drugs ahead of holiday season
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...